Hilary Eaton

R&D

Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.

News

ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.